Therapy for adults with refractory chronic immune thrombocytopenic purpura.
about
Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation?Predictors of response after laparoscopic splenectomy for immune thrombocytopenic purpura.Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy.Management of adult immune thrombocytopenia.Resolution of chronic idiopathic thrombocytopenia purpura following syngeneic peripheral blood progenitor transplant.Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia.Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis.Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.Comparison of thrombopoiesis during ITP and HIV-ITP and response to intravenous gammaglobulin treatment.Adult idiopathic thrombocytopenic purpura.Cardiobacterium hominis endocarditis associated with very severe thrombocytopenia and platelet autoantibodies.High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults.Postsplenectomy recurrence of thrombocytopenia with an accessory spleenEradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan.Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study.Recovery from idiopathic thrombocytopenic purpura (ITP) following right hemicolectomy for mucocele of appendix.A GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studies.Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura.[Adult autoimmune thrombocytopenia: diagnosis and treatment].An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation.Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisEpidemiology and pathophysiology of immune thrombocytopenic purpura.Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective.IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions.Conjugation of methotrexate to immunoglobulins kills macrophages by Fc receptor mediated uptake?Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature.Immune thrombocytopenic purpura: epidemiology and implications for patients.The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review.Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies.Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).Severe Thrombocytopenia in an Immune Thrombocytopenic Parturient Non-responder to Medical Line of Treatment: Anaesthetic Management for Splenectomy Combined with Caesarean Section.High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
P2860
Q33336653-361360EF-7F84-4B36-B737-09A054839681Q33336993-D5922658-FF69-4351-B5A7-C73839249166Q33337316-1D0E250E-48E1-4827-A7FE-1558A90A8E1AQ33338287-F8587D61-F13A-492C-861D-D5A2499553F1Q33339746-CD52C36A-7AFC-4021-B03E-FEC77B63E786Q33341012-7294D154-3F05-4397-929F-E0FDB56C9238Q33341032-D2B321BC-8558-4584-9BFF-6F556FE29F38Q33343948-F7519E8A-ACE8-4C19-889C-BDC98053C1B2Q33346561-C64A3758-A717-4F8B-8EF0-34B652C7983AQ33347074-732E72C9-CA98-4993-81A0-89073C528E40Q33347614-8709B7A7-D0CC-4758-BEAB-C59ACA8FB164Q33349710-5E0C1504-67D4-465B-A95A-DFA7FEA3228DQ33358032-CF14EE14-FF4B-44A3-A8AB-8F923269E338Q33361915-17E397BD-DE8A-4B8B-8CAD-BC0753B521D4Q33362143-C2FD7D38-0F62-442A-85F6-4E229B8FBA3CQ33363217-1EDE2F98-59D7-4AE2-BBAD-E912480E4C51Q33365171-9DB5706B-D908-432C-8B78-713B2565EB08Q33366703-7FA80F26-E0B2-45F4-8AFC-82BACF21695BQ33367682-D66A5BE0-9096-488F-A639-1B5A10884D54Q33367971-3D6596EC-DED0-4CBD-92B9-B863DC773F6EQ33369682-259E1CF1-1140-465A-89F0-EFE5114CE335Q33371795-3631C6DE-7665-40AB-BED6-120223566389Q33373074-F0069D82-A101-4761-A182-4374C2E3429AQ33374327-05FC642C-FBDF-4682-B620-9F6C22F38AA0Q33376705-6B9D7F8D-82DE-4375-9D3E-112BF582CAC3Q33378367-E1CC9BC4-C4E8-45A4-92D3-7D7B2BC841CCQ33378585-C3AC9213-CBC6-412E-B94F-E15783B5E844Q33378924-F234ABD6-A224-4299-B08F-ED69D59D2A6AQ33379596-3311F8BE-60C1-4142-91A1-8D00C722B52FQ33381122-44CDCF16-8298-4711-8B65-F7F81FB1F98BQ33383182-C4325390-DB34-4BDB-9626-080CD806D4B1Q33383464-137DFBD2-9EFB-4B94-9749-D11A0170CACBQ33386189-5F7078D3-E607-4EE1-9AF9-30A4704D79FAQ33388078-858B430E-DC38-41FB-9E23-A78F32DC34BBQ33390837-3BA74C12-614C-49BA-825B-D6BF54E602E2Q33395943-24D242F0-C645-4993-A3A8-B981FBF7B62BQ33400911-3BE30389-EB62-4AE7-BE66-54CBF4771C3EQ33406162-69D0D879-1C54-4BAB-9391-61416AC7523FQ33406310-95834E0D-02F9-4437-82EE-B02B702B9AF2Q33431850-412CACA0-2A8E-4854-94DC-21792D47A34E
P2860
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
@ast
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
@en
type
label
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
@ast
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
@en
prefLabel
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
@ast
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
@en
P1476
Therapy for adults with refractory chronic immune thrombocytopenic purpura.
@en
P2093
McMillan R
P304
P356
10.7326/0003-4819-126-4-199702150-00007
P407
P577
1997-02-01T00:00:00Z